

## Photobiomodulation (PBM) therapy for Geographic Atrophy

Photobiomodulation (PBM) therapy, a form of light therapy, is being explored as a potential treatment for geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD). Geographic atrophy involves the progressive degeneration of the retinal pigment epithelium (RPE), photoreceptors, and choriocapillaris, primarily in the macular region of the eye, leading to a loss of central vision.

Here's how photobiomodulation might work in the context of GA:

- 1. Cellular Activation:** PBM uses low-level light (usually red or near-infrared) to stimulate cellular activity. It is thought to enhance mitochondrial function, particularly by stimulating the activity of cytochrome c oxidase in the mitochondrial respiratory chain. This stimulation can increase ATP (adenosine triphosphate) production, leading to enhanced cell viability and function.
- 2. Reduction of Oxidative Stress:** Oxidative stress plays a significant role in the pathogenesis of AMD, including GA. PBM therapy may help to reduce oxidative stress in retinal cells, thereby potentially slowing the progression of GA.
- 3. Anti-inflammatory Effects:** PBM has demonstrated anti-inflammatory properties in various tissues. In the context of GA, reducing inflammation could be beneficial, as inflammation is a key factor in the progression of AMD.
- 4. Neuroprotection:** PBM might provide neuroprotective effects to the retinal cells, protecting photoreceptors and RPE cells from damage and apoptosis (programmed cell death).
- 5. Increased Blood Flow:** Improved blood flow to the retinal tissues, which can be facilitated by PBM, might provide better oxygenation and nutrient supply, potentially supporting the health of retinal cells.
- 6. Angiogenesis Modulation:** While angiogenesis (the formation of new blood vessels) is more relevant in the "wet" form of AMD, the modulation of this process might still play a role in managing GA.

### Clinical Studies and Considerations:

- The effectiveness of PBM in treating GA is still under investigation. Clinical trials are needed to establish its efficacy and safety.
- The optimal parameters for PBM treatment (such as wavelength, intensity, duration, and frequency of application) for GA are yet to be determined.
- It's important to differentiate between PBM for GA and treatments for "wet" AMD, which often involve anti-VEGF (vascular endothelial growth factor) injections to control abnormal blood vessel growth.

Patients with geographic atrophy should consult with their ophthalmologist or a retina specialist before considering PBM, as it is important to have a comprehensive understanding of the potential benefits and risks, as well as to consider the current state of research in this area.

Nicholas Lee 2024